0001479290-24-000104.txt : 20240702
0001479290-24-000104.hdr.sgml : 20240702
20240702174739
ACCESSION NUMBER: 0001479290-24-000104
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240630
FILED AS OF DATE: 20240702
DATE AS OF CHANGE: 20240702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Foley Mark J
CENTRAL INDEX KEY: 0001529196
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 241097364
MAIL ADDRESS:
STREET 1: ZELTIQ AESTHETICS INC.
STREET 2: 4698 WILLOW ROAD SUITE 100
CITY: PLEASANTON
STATE: CA
ZIP: 94588
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
BUSINESS PHONE: 6157247755
MAIL ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
wk-form4_1719956853.xml
FORM 4
X0508
4
2024-06-30
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001529196
Foley Mark J
C/O REVANCE THERAPEUTICS, INC.
1222 DEMONBREUN STREET, 20TH FLOOR
NASHVILLE
TN
37203
1
1
0
0
CEO
0
Common Stock
2024-06-30
5
A
0
E
1000
2.1845
A
995935
D
Common Stock
110913
I
See footnote
These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30,2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.
/s/ Dwight Moxie, Attorney-in-Fact
2024-07-02